单次低剂量艾斯基他明对患有易怒肠综合征的患者的疗效:随机对照试验的研究方案
Zhe Sun1, Lei Jiang1, Yan Xing1
1Department of Day Surgery, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China.
BMJ open
|June 23, 2025
概括
一次性低剂量埃斯基他明可以有效治疗易怒肠综合征 (IBS) 症状. 这项研究调查了胺胺.
科学领域:
- 胃肠病学 胃肠病学
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 刺激性肠综合征 (IBS) 是一种常见的肠-大脑相互作用障碍.
- 目前的IBS治疗方法往往是不令人满意的,尤其是严重的症状.
- 埃斯凯特胺显示出快速的抗抑郁作用,表明IBS的潜力.
研究的目的:
- 为了研究一次低剂量埃斯基坦胺对IBS的疗效.
- 评估胺对IBS症状严重程度和生活质量的影响.
主要方法:
- 单中心,随机,双盲,安慰剂对照试验.
- 每组92名患者 (乙胺与安慰剂) 通过轻度,中度和严重的IBS.
- 主要结局:IBS严重性评分系统;次要结局:QoL,便形式,焦虑,抑郁,身体症状.
主要成果:
- 在多个时间点上对IBS严重性评分系统的主要结果数据.
- 二次结果数据包括生活质量和心理评估.
- 不良事件将被系统地记录和分析.
结论:
- 假设单次低剂量埃斯基坦胺对IBS有效.
- 需要进一步的研究来确定胺在IBS治疗中的作用.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
313
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
313
Drugs for Treatment of Constipation-Predominant IBS
353
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
353
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
418
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
418
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
256
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
256
Irritable Bowel Syndrome III: Medical and Nursing Management
321
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
321
Electroconvulsive Therapy
205
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
205


